Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTG 007

Next Previous
X
Search
Drug Profile

PTG 007

Alternative Names: PTG-007

Latest Information Update: 28 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PolTREG
  • Class Antihyperglycaemics; Gene therapies; Regulatory T lymphocyte cell therapies
  • Mechanism of Action Regulatory T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Phase I/II Multiple sclerosis

Most Recent Events

  • 18 Nov 2024 PolTREG plans the phase II PreTreg trial forType 1 diabetes mellitus (In children, In adolescents) in Poland (Infusion), in December 2024 (NCT06688331) (EUCT2023-505226-33-00)
  • 24 Oct 2024 Phase-II clinical trials in Type 1 diabetes mellitus (In adolescents, In children) (Parenteral)
  • 16 Sep 2024 China’s National Intellectual Property Administration grants a patent for the intrathecal administration of PTG 007 in Multiple sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top